Prostate Cancer

References

Citations

1. American Cancer Society (2006). Cancer Facts and Figures 2006, pp. 1–56. Atlanta: American Cancer Society. Available online: http://www.cancer.org/docroot/STT/stt_0.asp.

2. Kantoff PW (2002). Prostate cancer. In DC Dale, DD Federman, eds., Scientific American Medicine, section 12, chap. 9. New York: WebMD.

3. Carter HB, Partin AW (2002). Diagnosis and staging of prostate cancer. In PC Walsh et al., eds., Campbell's Urology, 8th ed., vol. 4, pp. 3055–3079. Philadelphia: W.B. Saunders.

4. Gronberg H (2003). Prostate cancer epidemiology. Lancet, 361(9360): 859–864.

5. U.S. Preventive Services Task Force (2003). Screening for prostate cancer: Recommendations and rationale. American Family Physician, 67(4): 787–792.

6. Reiter RE, deKernion JB (2002). Epidemiology, etiology, and prevention of prostate cancer. In PC Walsh et al., eds., Campbell's Urology, 8th ed., vol. 4, pp. 3003–3024. Philadelphia: W.B. Saunders.

7. National Cancer Institute (2005). Prostate Cancer (PDQ): Prevention—Health Professional Version. Available online: http://www.nci.nih.gov/cancertopics/pdq/prevention/prostate/HealthProfessional/page3.

8. Bill–Axelson A, et al. (2005). Radical prostatectomy versus watchful waiting in early prostate cancer. New England Journal of Medicine, 352(19): 1977–1984.

9. Punglia RS, et al. (2003). Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. New England Journal of Medicine, 349(4): 335–342.

10. Scher HI, et al. (2005). Cancer of the prostate. In VT DeVita Jr et al., eds., Cancer: Principles and Practice of Oncology, 7th ed., pp. 1192–1259. Philadelphia: Lippincott Williams and Wilkins.

11. Long JP, et al. (2001). Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology, 57(3): 518–523.

12. Thompson IM, et al. (2003). The influence of finasteride on the development of prostate cancer. New England Journal of Medicine, 349(3): 213–222.

13. Roberts RO, et al. (2002). A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clinic Proceedings, 77(3): 217–218.

14. Schoonen WM, et al. (2005). Alcohol consumption and risk of prostate cancer in middle-aged men. International Journal of Cancer, 113(1): 133–140.

Other Works Consulted

• Ahmed HU, et al. (2007). Will focal therapy become a standard of care for men with localized prostate cancer? Nature Clinical Practice Oncology, 4(11): 632–642.

• Chen RC, et al. (2008). Treatment "mismatch" in early prostate cancer: Do treatment choices take patient quality of life into account? Cancer, 112(1): 61–68.

• D'Amico AV, et al. (2002). Radiation therapy for prostate cancer. In PC Walsh et al., eds., Campbell's Urology, 8th ed., vol. 4, pp. 3147–3170. Philadelphia: W.B. Saunders.

• Elkord E (2007). Immunology and immunotherapy approaches for prostate cancer. Prostate Cancer Prostatic Disease, 10(3): 224–236.

• Hartke DM, Resnick MI (2007). Radical perineal prostatectomy. In AJ Wein et al., eds., Campbell-Walsh Urology, 9th ed., vol. 3, pp. 2979–2984. Philadelphia: Saunders Elsevier.

• Iversen P, et al. (2004). Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study No. 6. Journal of Urology, 172(5, Part 1): 1871–1876.

• National Comprehensive Cancer Network and the American Cancer Society (2004). Prostate Cancer: Clinical Practice Guidelines in Oncology, version 1.2004. Jenkintown, PA: National Comprehensive Cancer Network.

• National Institutes of Health (2007). Prostate cancer genetics: Fact sheet. Available online: http://www.nih.gov/about/researchresultsforthepublic.

• Su L, Smith JA (2007). Laparoscopic and robotic-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy. In AJ Wein et al., eds. Campbell-Walsh Urology, 9th ed., vol.3, pp. 2985–3005. Philadelphia: Saunders Elsevier.

• Tsai HK, et al. (2007). Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute, 99(20): 1516–1524.

Go to previous section	Go to top of page	Go to next section
Author:	Bets Davis, MFA	Last Updated: July 24, 2006
Medical Review:	E. Gregory Thompson, MD - Internal Medicine Christopher G. Wood, MD, FACS - Urology/Oncology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.